Kepivance Side Effects
Generic Name: palifermin
Note: This page contains information about the side effects of palifermin. Some of the dosage forms included on this document may not apply to the brand name Kepivance.
Not all side effects for Kepivance may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.
For the Consumer
Applies to palifermin: intravenous powder for solution
In addition to its needed effects, some unwanted effects may be caused by palifermin (the active ingredient contained in Kepivance). In the event that any of these side effects do occur, they may require medical attention.
If any of the following side effects occur while taking palifermin, check with your doctor or nurse immediately:More common
- Skin rash (severe)
Some of the side effects that can occur with palifermin may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:More common
- Bad, unusual, or unpleasant (after) taste
- blurred vision
- burning, crawling, itching, numbness, prickling, "pins and needles", or tingling feelings
- change in taste
- difficulty with moving
- discoloration of the tongue
- flushing or redness of the skin
- increased sensitivity to pain
- increased sensitivity to touch
- itching skin
- muscle pain or stiffness
- pain in the joints
- pounding in the ears
- rash (mild)
- slow or fast heartbeat
- thickening of the tongue
- tingling in the hands and feet
- unusually warm skin
- redness or swelling of the vagina
- redness, swelling, or pain of the skin
- scaling of the skin on the hands and feet
- ulceration of the skin
For Healthcare Professionals
Applies to palifermin: intravenous powder for injection
Dermatologic side effects for palifermin (the active ingredient contained in Kepivance) in relation to placebo therapy have included rash (62% vs. 50%), pruritus (35% vs. 24%), and erythema (32% vs. 22%).
Skin rash was the most common serious side effect reported.
Clinical studies (n=409) reported the occurrence of grade 3 skin rash in 14 patients (9 palifermin, 5 placebo) resulting in the discontinuation of treatment in 7 patients (5 palifermin, 2 placebo).
Following the first 3 consecutive days of administration, the median time to cutaneous side effects is 6 days with a median duration of 5 days.
Following the first 3 consecutive days of administration, the median time to cutaneous side effects, including edema, is 6 days with a median duration of 5 days.
Other side effects for palifermin in relation to placebo therapy have included edema (28% vs. 21%), pain (16% vs. 11%), fever (39% vs. 34%) and perianal pain (12% vs. 5%). Other side effects of palifermin following a single 90 mcg/kg IV dose include fatigue (26%) and headache (23%).
Gastrointestinal side effects for palifermin (the active ingredient contained in Kepivance) in relation to placebo therapy have included mouth/tongue thickness and/or discoloration (17% vs. 8%) and altered taste (16% vs. 8%). Oral/perioral dysesthesia and white film coating of the mouth or tongue has also been reported.
Musculoskeletal side effects for palifermin (the active ingredient contained in Kepivance) in relation to placebo therapy have included arthralgia (10% vs 5%).
Dysthesias in palifermin (the active ingredient contained in Kepivance) treated patients have generally been reported as localized to the perioral region. In contrast, patients receiving placebo have generally reported dysthesias in extremities.
Nervous system side effects for palifermin in relation to placebo therapy have included dysthesias (12% vs. 7%). Types of dysthesias reported have included hyperesthesia, hypoesthesia, and paresthesia.
There are no available data on the effects of palifermin (the active ingredient contained in Kepivance) on stimulation of KGF receptor- expressing, non- hematopoietic tumors in patients.
At concentrations greater than 15 times the average therapeutic human concentration palifermin has been reported to enhance the growth of human epithelial tumor cell lines in vitro.
In nude mouse xenograft models, doses 25 and 67 times higher than the recommended human dose administered daily for 3 consecutive weeks and repeated weekly for 4 to 6 weeks may have resulted in a dose-dependent increase in the growth rate of 1 of 7 KGF receptor- expressing human tumor cell lines.
Oncologic side effects have included enhancement in the growth of human epithelial tumor cell lines in vitro and an increase in the rate of tumor cell line growth in a human carcinoma xenograft model.
Metabolic side effects for palifermin (the active ingredient contained in Kepivance) in relation to placebo therapy have included elevated serum lipase grade 3 (28% vs. 23%), elevated serum lipase grade 4 (11% vs. 5%), elevated serum amylase grade 3 (62% vs. 54%), and elevated serum amylase grade 4 (38% vs. 31%).
In clinical studies, the elevated serum lipase and amylase levels were reversible with peak increases recorded during the period of cytotoxic therapy. Levels returned to baseline by the day of PBPC infusion. There are no reports of required treatment intervention.
The increased amount of amylase is reported to be predominantly salivary in origin.
Hypertension was reported with doses of 60 mcg/kg and 80 mcg/kg in patients undergoing hematopoietic transplantation. This effect appeared to be transient. There are no reports of treatment discontinuation due to hypertension.
Cardiovascular side effects have included hypertension.
There have been reports of 2+ or greater proteinuria in patients treated with palifermin (the active ingredient contained in Kepivance) however, a causal relationship between palifermin and proteinuria has not been established.
Genitourinary side effects have included proteinuria.
In general, doses of 80 mcg/kg administered intravenously 3 doses prior to and 3 doses after myeloablative chemotherapy/TBI produced the same type of side effects seen with 60 mcg/kg doses; however, a higher level of severity was reported with the higher dose.
Respiratory side effects for palifermin (the active ingredient contained in Kepivance) in relation to placebo therapy have included cough (34% vs. 28%) and rhinitis (17% vs. 9%).
More about Kepivance (palifermin)
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.